Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Canada’s Duchesnay Gets Rights to Shionogi’s Osphena in North America
March 14, 2017
- Debiopharm Brings Towa before Supreme Court over Elplat
March 14, 2017
- 1st Line Use, Administration Interval Will Be Key Differentiator for Keytruda: MSD Japan Chief
March 14, 2017
- Yoshiki Ito Named as New Alexion Japan President
March 14, 2017
- Pfizer Initiates Voluntary Recall of EpiPen 0.3 mg in Japan
March 14, 2017
- UMN, Astellas Agree on Termination of Joint Flu Vaccine Programs
March 13, 2017
- Eisai CEO Has High Hopes on Combinations of Alzheimer’s Pipelines
March 10, 2017
- Takecab Most Heavily Pitched Drug in HP Market in January: Anterio
March 9, 2017
- Yutaka Shibata to Helm Asahi Kasei Pharma
March 9, 2017
- Pfizer’s FY2016 Japan Sales Slide 7.4% on Price Cuts, Generic Erosions
March 9, 2017
- Fujifilm Succeeds at Increasing Anti-Inflammatory Action of Mesenchymal Stem Cells, Expects Uses in Regenerative Medicine
March 9, 2017
- Average Drug R&D Spending in Japan Up 1.46 Billion Yen in FY2015
March 8, 2017
- Ethical Drug Sales Down 6.8% in January: Crecon
March 8, 2017
- Avelumab Filed in Japan for Merkel Cell Carcinoma: Merck Serono/Pfizer
March 8, 2017
- Taiho Forms Canadian Unit for Lonsurf Rollout
March 8, 2017
- Edoxaban Study in Post-PCI AF Patients Underway: Daiichi Sankyo
March 8, 2017
- Fujifilm, Kyowa Kirin JV Wins Humira Patent Litigation in UK
March 7, 2017
- Mochida, Fuji Yakuhin Link Arms on Hyperuricemia Candidate
March 7, 2017
- Maruho Group to See 1st Overseas Launch Next Month with Acne Med
March 7, 2017
- Kanako Kikuchi to Become Japan Chief of GSK
March 7, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…